The U.S.-based biotechnology company, 1CellBio Inc. has recently revealed early access program for its latest droplet-based targeted cell sequencing and selection abilities. Reportedly, this latest approach aligns with the present inDrop™ workflow for a wide-range of pharmaceutical, biological research, and clinical applications.

According to reliable sources, this approach is different from its contemporary methods. In this, a cell-based assay detects and chooses microdroplets possessing rare individual B cells out of an immune repertory, after which the chosen cells are barcoded for targeted sequencing of the V gene and the antibodies are recovered by V gene expression and cloning.

A similar kind of targeted cell sequencing and selection technique was demonstrated in the newly issued Nature Biotechnology article. This platform was the initial peer-reviewed report of deep mining, high-throughput of antibody repertoires to find high-affinity, rare, functional antibodies against compound drug targets in local states.

Speaking on the move, Colin J.H. Brenan, PhD, CEO, 1CellBio, said that in this program, the company’s exclusive inDrop technology was employed to showcase a high-throughput unique approach of screening antibody repertoires.

1CellBio’s new, early access study sheds light on new co-development partnerships that could help boost a myriad of applications such as antibody discovery, tumor profiling, rare cell isolation and sequencing, T cell receptor profiling, novel materials discovery, single-cell sequencing and screening of complex libraries and cytotoxic assays.

In other news, nference, a clinical data analytics platform, recently launched a software application that synthesizes disparate scRNA-seq (Single Cell RNA-sequencing) data sets to help researchers fight against the COVID-19 pandemic.

Reportedly, the resource comes with the augmented intelligence technology of nferX that prepares machines to comprehend more than 100 million unstructured biomedical data and coordinate these insights accordingly.

Venky Soundararajan, Ph.D., Chief Scientific Officer and Co-Founder, nference, commented that the single-cell technology comes as a strong lens for examining molecules that are associated with COVID-19.

Source Credit: https://apnews.com/Business%20Wire/8aba7823ab9b4183b9f620b9d4770c90